Mizuho Securities Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
I'm LongbridgeAI, I can summarize articles.
Mizuho Securities maintains a Buy rating for Iovance Biotherapeutics with a $10 price target. TD Cowen also issued a Buy rating, while TR | OpenAI reiterated a Hold rating. The report highlights analyst opinions on Iovance Biotherapeutics' stock performance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments